Day: July 25, 2024

Form 8.3 – AXA INVESTMENT MANAGERS: Ascential plc

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION (a)   Full name of discloser: AXA Investment Managers S.A. (b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree Ascential plc (d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:   (e)   Date position held/dealing undertaken:        For an opening...

Continue reading

Nasdaq Announces Quarterly Dividend of $0.24 Per Share

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) — The Board of Directors of Nasdaq, Inc. (Nasdaq: NDAQ) has declared a regular quarterly dividend of $0.24 per share on the company’s outstanding common stock. The dividend is payable on September 27, 2024 to shareholders of record at the close of business on September 13, 2024. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors. About Nasdaq Nasdaq (Nasdaq: NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of...

Continue reading

Lakeland Financial Reports Second Quarter Net Income of $22.5 million, and Reaches $5.0 Billion in Total Loans, Representing 5% Annual Average Loan Growth

WARSAW, Ind., July 25, 2024 (GLOBE NEWSWIRE) — Lakeland Financial Corporation (Nasdaq Global Select/LKFN), parent company of Lake City Bank, today reported net income of $22.5 million for the three months ended June 30, 2024, which represents an increase of $7.9 million, or 54%, compared with net income of $14.6 million for the three months ended June 30, 2023. Diluted earnings per share were $0.87 for the second quarter of 2024 and increased 53% compared to $0.57 for the second quarter of 2023. On a linked quarter basis, net income decreased $852,000, or 4%, from first quarter 2024 net income of $23.4 million and diluted earnings per share decreased $0.04 or 4% from $0.91 at March 31, 2024. Pretax pre-provision earnings, which is a non-GAAP measure, were $35.4 million for the three months ended June 30, 2024, an increase of $18.1...

Continue reading

Perella Weinberg Announces Partner Promotions

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) — Perella Weinberg Partners (NASDAQ:PWP), a leading global independent advisory firm, today announced the promotion of four Managing Directors to Partners of the Firm. William Glass – Healthcare, New York Alexandra Gottschalk – Chief Financial Officer, Houston Sam Tanzer – Financing & Capital Solutions, New York Rebekah Weissburg – Chief Human Resources Officer, New York “We are pleased to announce the promotion of Will, Alex, Sam and Rebekah to Partner. Each has made meaningful contributions to our business and culture, and each has had an unwavering commitment to upholding our core values of trust, integrity and teamwork,” said Andrew Bednar, Chief Executive Officer. “Our new Partners will continue to lead our talented teams in putting clients first, enhancing our franchise, and...

Continue reading

Valley National Bancorp Announces Second Quarter 2024 Results

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) — Valley National Bancorp (NASDAQ:VLY), the holding company for Valley National Bank, today reported net income for the second quarter 2024 of $70.4 million, or $0.13 per diluted common share, as compared to the first quarter 2024 net income of $96.3 million, or $0.18 per diluted common share, and net income of $139.1 million, or $0.27 per diluted common share, for the second quarter 2023. Excluding all non-core income and charges, our adjusted net income (a non-GAAP measure) was $71.6 million, or $0.13 per diluted common share, for the second quarter 2024, $99.4 million, or $0.19 per diluted common share, for the first quarter 2024, and $147.1 million, or $0.28 per diluted common share, for the second quarter 2023. See further details below, including a reconciliation of our non-GAAP adjusted...

Continue reading

AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease

AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease Treatment of first randomized person with preclinical AD expected this quarter Phase 2b ReTain trial is fully funded and conducted by development partner Lausanne, Switzerland, July 25, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its active-immunotherapy candidate, ACI-35.030 (now called JNJ-2056), targeting the pathologic form of the Tau protein, phosphorylated Tau (pTau), has received Fast Track designation from the U.S. Food and Drug Administration (FDA). The recently initiated Phase 2b clinical trial ReTain is currently recruiting participants with preclinical Alzheimer’s disease, where individuals have yet to show...

Continue reading

Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results

Expands AI/ML driven offering to include novel oncology biomarker discovery to predict patient outcomes and drug response in oncology Biomarker discovery market estimated by third party research to be $51.5 billion in 2024 PITTSBURGH, July 25, 2024 (GLOBE NEWSWIRE) — Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it is expanding its AI/ML driven drug discovery platform to pursue discovery of novel biomarkers that can be used to predict patient outcomes and drug response in oncology. Predictive Oncology’s biomarker discovery initiative stems, in part, from results obtained in the retrospective ovarian cancer study with UPMC Magee-Womens Hospital, which were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. In that study, Predictive...

Continue reading

FirstCash Reports Second Quarter Operating Results; U.S. Pawn Fees Grow 22%, Driving 25% Increase in U.S. Pawn Segment Earnings; 47 Pawn Locations Added in Second Quarter Through Acquisitions and New Store Openings; Quarterly Cash Dividend Increased to $0.38 per Share

FORT WORTH, Texas, July 25, 2024 (GLOBE NEWSWIRE) — FirstCash Holdings, Inc. (“FirstCash” or the “Company”) (Nasdaq: FCFS), the leading international operator of more than 3,000 retail pawn stores and a leading provider of retail point-of-sale (“POS”) payment solutions through American First Finance (“AFF”), today announced operating results for the three and six month periods ended June 30, 2024. The Company also announced that the Board of Directors declared a quarterly cash dividend of $0.38 per share, an increase of 9% compared to the previous quarterly dividend of $0.35 per share, to be paid in August 2024. Mr. Rick Wessel, chief executive officer, stated, “We are pleased to report another quarter of record revenues and strong earnings growth. The U.S. pawn segment delivered outstanding results with a 25% increase in second...

Continue reading

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the third cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a novel modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD). GA affects approximately 1 million people in the United States. “Currently, there are two FDA approved anti-complement therapies for GA, which targets only one pathway for a disease that has a multifactorial and complex etiology,” said Majda Hadziahmetovic, MD, Associate Professor of Ophthalmology, Vitreoretinal...

Continue reading

Bombardier Posts Double-Digit Growth Across Key Metrics Including Deliveries, Revenues, Services and Profitability, Affirms Full Year Guidance   

Second quarter 2024 aircraft deliveries reached 39 units and total revenues climbed to $2.2 billion, with Services contributing $507 million, reflecting year-over-year growth of 34%, 32% and 18%, respectively. Adjusted EBITDA(1) of $335 million for the second quarter was up 22% year-over-year, and adjusted EBITDA margin(2) was 15.2%. Reported EBIT for the second quarter was $191 million. Adjusted EPS(2) was positive at $1.04 for the second quarter, with diluted EPS(3) at $0.12. Free cash flow usage(1) of $68 million represented a $154 million improvement compared to the same quarter of 2023. Reported cash flow usage from operating activities and net additions to PP&E and intangible assets were $31 million and $37 million, respectively.​ Backlog(4) as at June 30, 2024 was $14.9 billion on unit book-to-bill(5) of 1.0, reflecting consistent...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.